GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Akebia Therapeutics
Shares of Akebia Therapeutics, a biopharmaceutical company focused on treating kidney diseases, reflect the binary risks of the biotech sector. Their price trajectory is determined by regulatory decisions (FDA) on their key drug and the results of clinical trials.
Share prices of companies in the market segment - Pharma kidney
Akebia Therapeutics is a biopharmaceutical company specializing in the development of drugs for the treatment of kidney diseases. We've classified it in the "Pharma: Kidney" segment, and the chart below reflects the overall dynamics and investor sentiment in this highly specialized biotech area.
Broad Market Index - GURU.Markets
Akebia Therapeutics is a biopharmaceutical company specializing in the development of drugs for the treatment of kidney diseases. It is a component of the GURU.Markets index, and the chart below shows how its stock compares to the market, reflecting investor expectations.
Change in the price of a company, segment, and market as a whole per day
AKBA - Daily change in the company's share price Akebia Therapeutics
The volatility of Akebia Therapeutics, a biopharmaceutical company, reflects risks associated with regulatory decisions. Change_co measures sensitivity to FDA news regarding its anemia drug. This parameter is important for formulas on System.GURU.Markets that analyze binary events in biotech.
Daily change in the price of a set of shares in a market segment - Pharma kidney
Akebia Therapeutics, Inc. is a biotech company. This chart highlights the sector's extreme volatility. Comparison with AKBA, which focuses on kidney disease treatments, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Akebia is a biopharmaceutical company specializing in drugs for the treatment of kidney diseases. Biotechnology is a volatile sector. The chart below shows average daily fluctuations in this sector, providing context for analyzing Akebia's stock performance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Akebia Therapeutics
Akebia is a biopharmaceutical company specializing in the treatment of kidney diseases. Its shares are driven by news of clinical trials. This high volatility, driven by innovation, is a significant component of the overall "noise" and stock market dynamics.
Annual dynamics of market capitalization of the market segment - Pharma kidney
Akebia Therapeutics, Inc. is a biopharmaceutical company focused on treating kidney diseases. Its success depends on regulatory decisions and the commercialization of its key drug. The chart below shows how its regulatory approval process and competitive environment are impacting its volatile performance in the pharmaceutical sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Akebia is a biopharmaceutical company whose stock performance is driven by the sales success of its drugs and progress in research. The company's business is not dependent on economic cycles. The chart reflects biotech events rather than macroeconomic data, making it a non-cyclical growth story.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Akebia Therapeutics
Akebia, a biopharmaceutical company focused on treating kidney diseases, has monthly fluctuations on its chart reflecting regulatory decisions regarding its drugs, as well as the commercial success of its already approved drug. These events are key to the company's future and determine investor sentiment.
Monthly dynamics of market capitalization of the market segment - Pharma kidney
Akebia Therapeutics specializes in drugs for the treatment of kidney diseases, particularly anemia associated with chronic kidney disease. The pharmaceutical sector in this area is closely monitoring regulatory decisions and clinical trial results. The chart will show the overall dynamics and investor sentiment in this narrow therapeutic niche.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Akebia Therapeutics is a biopharmaceutical company focused on treating kidney diseases. Its future depends on the approval and commercial success of its drugs. Share price movements are driven by FDA decisions and clinical trial news, making it highly volatile and out of touch with overall market trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Akebia Therapeutics
Akebia Therapeutics is a biotech company focused on treating kidney diseases. Its weekly stock price reflects binary events: a positive or negative FDA decision on its drug could trigger a dramatic rise or fall.
Weekly dynamics of market capitalization of the market segment - Pharma kidney
Akebia Therapeutics is a biotech company whose fate hinges on a single drug. Comparing its weekly performance to the biotech sector is pointless. The chart shows how binary events—news about the FDA's decision—cause its shares to soar or plummet by hundreds of percent, living in a separate universe.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Shares of Akebia, a biotech company, exist in a world of their own, far removed from macroeconomic news. Their performance is determined by FDA decisions. A chart comparing the stock to the S&P 500 clearly demonstrates how the stock can rise or fall, completely ignoring the broader market.
Market capitalization of the company, segment and market as a whole
AKBA - Market capitalization of the company Akebia Therapeutics
Akebia Therapeutics' market capitalization tells the dramatic story of the battle to secure approval for a new drug to treat anemia in patients with chronic kidney disease. The company's timeline reflects FDA decisions, including the denial of approval, and the company's subsequent efforts to achieve success. It's a visual representation of all the challenges involved in bringing a drug to market.
AKBA - Share of the company's market capitalization Akebia Therapeutics within the market segment - Pharma kidney
Akebia Therapeutics is a biopharmaceutical company focused on developing treatments for kidney diseases. Its market share reflects investor expectations for the commercial success of its products. The chart below shows the market's assessment of its market share and prospects in the competitive kidney drug market.
Market capitalization of the market segment - Pharma kidney
Akebia Therapeutics specializes in developing drugs to treat kidney diseases. The chart below shows the overall market capitalization of the pharmaceutical sector. It gives an idea of the scale of the market in which Akebia operates and the high stakes associated with the approval or rejection of its key drugs by regulators.
Market capitalization of all companies included in a broad market index - GURU.Markets
The Akebia Therapeutics line on this chart tells the story of the fight against anemia in kidney disease patients. The company's market capitalization rises and falls depending on regulatory decisions (like the FDA's) regarding its drugs. This is a dramatic visualization of how a single official decision can determine the fate of a biotech company.
Book value capitalization of the company, segment and market as a whole
AKBA - Book value capitalization of the company Akebia Therapeutics
Akebia Therapeutics' book value is its financial reserves and rights to drugs for the treatment of anemia associated with chronic kidney disease. This is the capital the company uses to navigate complex regulatory procedures. The chart below shows how FDA decisions and the need for additional funding impacted this pharmaceutical company's capital base.
AKBA - Share of the company's book capitalization Akebia Therapeutics within the market segment - Pharma kidney
Akebia Therapeutics develops and commercializes drugs for the treatment of kidney diseases. The company focuses on science and marketing rather than manufacturing. The chart shows a modest share of physical assets, reflecting its business model, which often outsources manufacturing to partners.
Market segment balance sheet capitalization - Pharma kidney
Developing kidney disease drugs like Akebia's is a knowledge-intensive but relatively "easy" business at the R&D stage. Its value lies in its patents. Compared to the capital-intensive pharmaceutical sector, the company's model doesn't require the ownership of large manufacturing plants.
Book value of all companies included in the broad market index - GURU.Markets
Akebia Therapeutics' book value is not derived from its plants, but primarily from its intellectual property and capital invested in the development and commercialization of drugs for the treatment of kidney diseases, particularly anemia. Its assets reflect its financial resources for research. The chart illustrates its scale in the pharmaceutical world.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Akebia Therapeutics
Akebia, a biopharmaceutical company, often trades below its book value. This reflects market skepticism about the prospects of its anemia treatment following regulatory setbacks, despite the company still having the capital to operate.
Market to book capitalization ratio in a market segment - Pharma kidney
Akebia Therapeutics is a pharmaceutical company focused on treating kidney diseases. Its valuation on this chart is highly dependent on regulatory (FDA) decisions regarding its drugs. This reflects binary risk: approval can lead to a rise, while rejection can lead to a fall.
Market to book capitalization ratio for the market as a whole
Akebia Therapeutics is a biopharmaceutical company focused on treating kidney diseases. Its valuation is heavily dependent on regulatory decisions (FDA approval) and the commercial success of its drugs. For Akebia, this metric reflects the binary nature of biotech risk: either major success or major failure, which sets it apart from the market average.
Debts of the company, segment and market as a whole
AKBA - Company debts Akebia Therapeutics
Akebia Therapeutics, a biopharmaceutical company commercializing drugs to treat anemia associated with kidney disease, uses debt financing to support its product launches and ongoing research. This chart shows the company's financial needs during the challenging transition from R&D to full-scale sales in a competitive market.
Market segment debts - Pharma kidney
Akebia Therapeutics is a biopharmaceutical company focused on treating kidney diseases. Its path has been challenging, including a drug application denial from the FDA. This chart shows how the company is managing its challenging financial situation and debt load while continuing to pursue approval and commercialization in a highly competitive environment.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Akebia Therapeutics
Akebia Therapeutics specializes in drugs for the treatment of kidney diseases, particularly anemia associated with chronic kidney disease. The process of obtaining regulatory approval (FDA) is lengthy and costly. This chart shows the company's debt load, illustrating the financial risks it faces in commercializing its pharmaceutical developments.
Market segment debt to market segment book capitalization - Pharma kidney
Akebia Therapeutics is a biopharmaceutical company focused on kidney disease treatments. Its financial health is largely dependent on regulatory decisions and commercialization success. This chart shows how the company finances its operations, comparing its debt load to the market capitalization of the entire pharmaceutical sector.
Debt to book value of all companies in the market
Akebia Therapeutics specializes in drugs for kidney diseases, particularly anemia. The pharmaceutical company's journey from lab to pharmacy is long and expensive. How heavily does Akebia rely on debt? This chart of total market debt provides context for assessing its financial strength on this risky path.
P/E of the company, segment and market as a whole
P/E - Akebia Therapeutics
Akebia Therapeutics is a biopharmaceutical company focused on developing treatments for kidney diseases. This chart shows how investors assess the prospects of its lead drug after receiving or denying regulatory approval. The assessment is highly dependent on FDA decisions and the drug's commercial potential.
P/E of the market segment - Pharma kidney
Akebia Therapeutics is a biopharmaceutical company specializing in the treatment of kidney diseases. Its primary product is aimed at treating anemia associated with chronic kidney disease. This chart shows the average valuation for the sector, allowing investors to assess the commercial potential and risks associated with Akebia's drugs.
P/E of the market as a whole
Akebia Therapeutics is a biopharmaceutical company focused on treating kidney diseases. Its fate, like many in the industry, hinges on regulatory decisions and the commercial success of its drugs. Does this chart illustrate the extent to which Akebia investors are ignoring the broader market picture, betting solely on its specific case?
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Akebia Therapeutics
Akebia Therapeutics is a biopharmaceutical company focused on developing treatments for kidney diseases. This chart reflects analyst expectations regarding the potential approval and commercial success of its key drug. The company's future revenue is entirely dependent on regulatory decisions and market acceptance.
%20P%2FE%20Akebia%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Akebia-Therapeutics&v=1772644080832 "Chart of the company's future (projected) P/E Akebia Therapeutics")
Future (projected) P/E of the market segment - Pharma kidney
Akebia Therapeutics specializes in drugs for the treatment of kidney disease complications, particularly anemia. The company's future depends heavily on regulatory approval decisions (such as the FDA). The chart shows forecasts for the pharmaceutical industry. This allows us to assess how market expectations for Akebia differ from general trends, given its binary risks.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20kidney&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-kidney&v=1772644080834 "Future (projected) P/E graph of the market segment - Pharma kidney")
Future (projected) P/E of the market as a whole
Akebia Therapeutics is a biopharmaceutical company focused on treating kidney diseases. Its valuation depends on the approval and commercial success of its drugs. This market sentiment graph is important because it impacts the company's ability to raise capital to bring its products to market and fund further research.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772644080847 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Akebia Therapeutics
Akebia Therapeutics specializes in drugs for the treatment of kidney diseases, particularly anemia associated with chronic kidney disease. The company's financial results reflect the balance between revenue from approved drugs and the costs of bringing new ones to market. This chart illustrates the complex commercialization path in the pharmaceutical industry.
Profit of companies in the market segment - Pharma kidney
Akebia Therapeutics develops drugs to treat kidney diseases, specifically anemia associated with chronic kidney disease. This chart illustrates the overall state of the pharmaceutical sector. Akebia's success depends on regulatory approval and its ability to compete with existing treatments. The sector's profitability impacts its opportunities for partnerships and commercialization.
Overall market profit
Akebia Therapeutics specializes in drugs for the treatment of kidney diseases, particularly anemia associated with chronic kidney disease. The company's success depends on regulatory approval and the ability of the healthcare system to pay for new drugs. Overall economic stability, reflected in this chart, is important for sustainable financing of the healthcare sector.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Akebia Therapeutics
Akebia Therapeutics specializes in developing drugs for the treatment of kidney diseases. The company's key product is aimed at combating anemia in patients with chronic kidney disease. This timeline reflects analyst expectations regarding the approval and commercial launch of their drug, which is the primary factor determining the company's future.
%20profit%20of%20the%20company%20Akebia%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Akebia-Therapeutics&v=1772644080881 "Graph of future (projected) profit of the company Akebia Therapeutics")
Future (predicted) profit of companies in the market segment - Pharma kidney
Akebia Therapeutics is a biopharmaceutical company focused on developing treatments for kidney diseases. Its core value lies in the potential approval and success of its lead candidate. This chart, which reflects general forecasts for the pharmaceutical sector, helps understand the market context and expectations for companies bringing new therapeutic solutions to market.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20kidney&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-kidney&v=1772644080887 "Graph of future (predicted) profits of companies in a market segment - Pharma kidney")
Future (predicted) profit of the market as a whole
Akebia Therapeutics is a biopharmaceutical company focused on treating kidney diseases. Its primary driver is clinical trial results. However, the overall profit forecast shown in this chart impacts the investment climate and valuation of companies in the biotech sector, which is important for its shareholders.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772644080901 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Akebia Therapeutics
Akebia Therapeutics is a biopharmaceutical company focused on treating kidney diseases. Because the company may be in the commercialization or development stage, this chart is important. It shows how investors assess the revenue potential of its drugs, weighing regulatory risks and the size of the addressable market to estimate future cash flows.
P/S market segment - Pharma kidney
Akebia Therapeutics specializes in drugs for the treatment of complications associated with kidney disease. The company's revenue depends on the approval and successful launch of its key drug. This chart shows the average valuation in the pharmaceutical sector, providing investors with context for understanding how the market views Akebia's commercial prospects.
P/S of the market as a whole
Akebia Therapeutics is a biopharmaceutical company focused on developing drugs for the treatment of kidney diseases. Its success depends on clinical trial results and regulatory approval. This chart, which reflects market revenue estimates, serves as a proxy for Akebia's expectations. It shows the value investors attribute to its research and development in anticipation of future sales.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Akebia Therapeutics
Akebia Therapeutics is a biopharmaceutical company focused on developing treatments for kidney diseases. Its future depends on regulatory decisions and the success of clinical trials. This timeline reflects investor expectations regarding the potential approval and commercial launch of its key drugs, which could dramatically impact revenue.
%20P%2FS%20Akebia%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Akebia-Therapeutics&v=1772644080941 "The graph of the company's future (projected) P/S Akebia Therapeutics")
Future (projected) P/S of the market segment - Pharma kidney
Akebia Therapeutics is a biopharmaceutical company specializing in the development of drugs for the treatment of kidney diseases. Its key product is aimed at treating anemia associated with chronic kidney disease. This chart shows average future revenue expectations in the pharmaceutical sector. It allows for a comparison of how the market assesses the commercial potential of Akebia's drugs.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20kidney&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-kidney&v=1772644080949 "Future (projected) P/S market segment graph - Pharma kidney")
Future (projected) P/S of the market as a whole
Akebia Therapeutics specializes in developing drugs to treat complications associated with kidney disease. The chart below shows how the market as a whole views its revenue growth prospects. Akebia's commercial success depends on regulatory approval and the ability of its drugs to become a new standard of care, which could significantly impact the multibillion-dollar nephrology market.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772644080952 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Akebia Therapeutics
This chart illustrates the revenue of Akebia Therapeutics, a biopharmaceutical company specializing in kidney disease treatments. Its revenue is generated from sales of approved drugs and could grow significantly if new products are approved. The trend reflects the commercial success of its therapies and their acceptance by the medical community.
Sales of companies in the market segment - Pharma kidney
Akebia Therapeutics is a biopharmaceutical company specializing in the development of drugs for the treatment of kidney diseases. This chart shows revenue in the nephrology sector. Akebia's drugs, aimed at treating anemia in patients with chronic kidney disease, could become a new standard of care, which could significantly impact the structure of this market.
Overall market sales
Akebia Therapeutics is a biopharmaceutical company focused on treating kidney diseases. Its success depends on the approval and commercialization of its drugs. The overall economic situation, shown in this chart, impacts the healthcare system and its ability to finance innovative treatments.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Akebia Therapeutics
Akebia Therapeutics specializes in drugs for the treatment of kidney diseases. The company's future revenue depends on the approval and successful launch of new drugs. This chart shows analysts' assessments of the commercial prospects of the company's flagship drug and its potential in the global market.
%20sales%20of%20the%20company%20Akebia%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Akebia-Therapeutics&v=1772644080970 "Schedule of future (projected) sales of the company Akebia Therapeutics")
Future (projected) sales of companies in the market segment - Pharma kidney
Akebia Therapeutics specializes in developing drugs to treat complications associated with kidney disease, particularly anemia. The company's success depends on regulatory approval and its ability to compete in a highly competitive market. This forecast for the pharmaceutical sector highlights the overall market potential in which Akebia is seeking to capture a share.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20kidney&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-kidney&v=1772644080990 "Schedule of future (projected) sales of companies in the market segment - Pharma kidney")
Future (projected) sales of the market as a whole
Akebia Therapeutics specializes in drugs for the treatment of kidney diseases, particularly anemia. The company's success depends on regulatory approval and its ability to compete in the pharmaceutical market. This chart reflects the overall economic backdrop, but for Akebia, the key factors are clinical trial results and FDA approvals, which determine its commercial potential.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772644080994 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Akebia Therapeutics
Akebia Therapeutics specializes in drugs for the treatment of kidney diseases. While commercializing its first product, the company incurs significant marketing and manufacturing expenses. This chart illustrates the balance between initial revenues and the ongoing investments required to gain market share.
Market segment marginality - Pharma kidney
#VALUE!
Market marginality as a whole
Akebia Therapeutics is a biopharmaceutical company focused on developing treatments for kidney diseases. Their key product is designed to combat anemia associated with chronic kidney disease. This overall profitability curve has little impact on their operations. Demand for their drugs is driven by patient medical needs, not economic cycles.
Employees in the company, segment and market as a whole
Number of employees in the company Akebia Therapeutics
Akebia Therapeutics is a biopharmaceutical company specializing in the treatment of kidney diseases. Its team size reflects its current stage of development. As it approaches potential approval and product launch, this graph will show growth through the hiring of sales and marketing specialists.
Share of the company's employees Akebia Therapeutics within the market segment - Pharma kidney
Akebia Therapeutics focuses on developing treatments for patients with kidney disease. This chart reflects the company's workforce weight in its pharmaceutical niche. This indicator's dynamics are directly related to the intensity of clinical trials and the size of the scientific team working to create new therapeutic solutions to improve the lives of millions of people.
Number of employees in the market segment - Pharma kidney
Akebia Therapeutics specializes in developing drugs for the treatment of kidney diseases. This chart shows employment trends in the pharmaceutical sector, focusing on nephrology. Fluctuations in headcount, particularly in research and clinical trials, are often related to key drug development milestones, regulatory decisions, and the competitive market environment.
Number of employees in the market as a whole
Akebia Therapeutics specializes in developing drugs to treat kidney diseases. The company's flagship product is designed to combat anemia associated with chronic kidney disease. This figure demonstrates how pharmaceutical companies working to treat common chronic diseases are impacting the healthcare sector and creating jobs.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Akebia Therapeutics (AKBA)
Akebia Therapeutics is a biotech company specializing in the treatment of kidney diseases. This chart reflects the valuation of its intellectual capital. The company's value is largely dependent on market expectations for its drugs (approved and in development). The chart shows the market valuation of this drug portfolio and associated patents per employee engaged in research and commercialization.
%20of%20the%20company%20Akebia%20Therapeutics%20(AKBA)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Akebia-Therapeutics-AKBA&v=1772644081073 "Chart of market capitalization per employee (in thousands of dollars) of the company Akebia Therapeutics (AKBA)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma kidney
Akebia Therapeutics is a biopharmaceutical company focused on treating kidney diseases. Its value is determined by its pipeline and clinical trial results. This chart shows how investors evaluate the company's scientific potential and commercial prospects, with intellectual property playing a key role, not headcount.
%20by%20market%20segment%20-%20Pharma%20kidney&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-kidney&v=1772644081086 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma kidney")
Market capitalization per employee (in thousands of dollars) for the overall market
Akebia Therapeutics is a biopharmaceutical company focused on developing treatments for kidney diseases. The chart reflects the valuation of a company whose fate is closely tied to regulatory decisions. The cost per employee can fluctuate sharply depending on news of the approval or rejection of its key drugs.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772644081095 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Akebia Therapeutics (AKBA)
Akebia Therapeutics is a biotech company specializing in drugs for kidney diseases, particularly anemia. The company faced regulatory challenges in launching its key drug. This chart shows the R&D company's struggle to reach the market: high personnel and research costs amid uncertain future revenues.
%20Chart%20Akebia%20Therapeutics%20(AKBA)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Akebia-Therapeutics-AKBA&v=1772644081105 "Company Profit Per Employee (in thousands of dollars) Chart Akebia Therapeutics (AKBA)")
Profit per employee (in thousands of dollars) in the market segment - Pharma kidney
Akebia Therapeutics (AKBA) is a biopharmaceutical company focused on treating kidney disease. Their drug Auryxia is approved, but their primary focus is on Vadadustat. This metric reflects a complex balance: the company generates revenue from one drug but incurs significant R&D and commercialization costs for another.
%20in%20the%20market%20segment%20-%20Pharma%20kidney&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-kidney&v=1772644081118 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma kidney")
Profit per employee (in thousands of dollars) for the market as a whole
Akebia Therapeutics (AKBA) is a biopharmaceutical company whose drug (Vafseo) for the treatment of anemia in CKD is approved in Europe and Japan, but not in the US. They also have another drug. This chart shows how revenues (primarily royalties) cover the enormous costs of R&D and efforts to gain approval in the US.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772644081122 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Akebia Therapeutics (AKBA)
Akebia Therapeutics specializes in kidney disease treatments. This chart reflects the commercial potential of its developments. Following approval of a new drug, growth in this indicator will indicate a successful market launch and the sales team's effectiveness in reaching physicians and medical institutions.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Akebia-Therapeutics-AKBA&v=1772644081134 "Sales chart per company employee Akebia Therapeutics (AKBA)")
Sales per employee in the market segment - Pharma kidney
Akebia Therapeutics specializes in drugs for the treatment of kidney diseases, particularly anemia. This chart shows the productivity of their commercial and scientific teams. It measures revenue per employee, allowing investors to evaluate their effectiveness in drug development and sales compared to other companies in the segment.
Sales per employee for the market as a whole
Akebia Therapeutics (AKBA) is a biopharmaceutical company focused on treating kidney diseases. The company has an approved drug but has faced regulatory challenges in the US. This chart shows how successfully the company's commercialization team generates sales revenue (primarily outside the US) while maintaining a significant R&D staff.
Short shares by company, segment and market as a whole
Shares shorted by company Akebia Therapeutics (AKBA)
Akebia Therapeutics is another company focused on treating kidney disease. Its key drug for treating anemia associated with CKD has encountered difficulties in gaining FDA approval. This chart shows the bets of "bears" who don't believe the company will overcome regulatory hurdles or that its drug will be competitive.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Akebia-Therapeutics-AKBA&v=1772644081143 "Short Shares Chart for the Company Akebia Therapeutics (AKBA)")
Shares shorted by market segment - Pharma kidney
Akebia Therapeutics is a biotech company focused on treating kidney disease. Their key drug (Vadadustat) is an anemia pill for dialysis patients. This indicator reflects skepticism. "Shorts" here are bets that their drug will fail to receive FDA approval or will lose out to competitors.
Shares shorted by the overall market
Akebia Therapeutics is a biopharmaceutical company focused on treating kidney disease. Like many biotechs without stable profits, its shares are extremely volatile. When this chart shows rising general market fear, investors flee risk. AKBA shares are becoming hostage not only to trial data but also to general panic.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Akebia Therapeutics (AKBA)
Akebia Therapeutics is a biotech company focused on kidney disease treatments. Its shares are volatile and dependent on R&D and FDA decisions. A chart reading above 70 may reflect positive news. Oversold territory (<30) is often associated with setbacks or regulatory issues.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Akebia-Therapeutics-AKBA&v=1772644081163 "RSI 14 indicator chart for the company's stock Akebia Therapeutics (AKBA)")
RSI 14 Market Segment - Pharma kidney
Akebia (AKBA) is a biotech company focused on treating *anemia* caused by chronic kidney disease (CKD). The RSI_14_Seg for "Pharma kidney" (biotech) shows the overall sentiment. The chart helps us understand: is AKBA's volatility a reaction to its trials or is the entire sector overheated?
RSI 14 for the overall market
Akebia (AKBA) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast AKBA (Akebia Therapeutics)
Akebia Therapeutics (AKBA) is a biopharmaceutical company focused on kidney disease. Its drug Auryxia has been approved, but the primary focus is on the potential approval of Vafseo (a drug for anemia in CKD). This chart shows the average analyst forecast. Their price targets are almost entirely dependent on the FDA's approval and the market potential of Vafseo.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-AKBA-Akebia-Therapeutics&v=1772644081198 "A chart showing analyst consensus forecasts for the expected stock price. AKBA (Akebia Therapeutics)")
The difference between the consensus estimate and the actual stock price AKBA (Akebia Therapeutics)
Akebia Therapeutics (AKBA) is a biopharmaceutical company whose lead drug (Vadadustat) for the treatment of anemia associated with kidney disease has received approval but is struggling for market share. This chart shows their R&D and commercialization assessment. It measures the gap between the price and the consensus target, reflecting analysts' confidence in the commercial success of their drug.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-AKBA-Akebia-Therapeutics&v=1772644081205 "A chart showing the difference between the consensus forecast and the actual stock price. AKBA (Akebia Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Pharma kidney
Akebia Therapeutics (AKBA) is a biopharmaceutical company focused on treating anemia associated with chronic kidney disease. Its drug, Vafseo, is a pill alternative to EPO injections. This chart shows general expectations for the kidney pharmaceutical sector, reflecting whether experts believe the new drug is marketable.
Analysts' consensus forecast for the overall market share price
Akebia Therapeutics (AKBA) is a biopharmaceutical company focused on treating kidney diseases. Their key drug treats anemia associated with chronic kidney disease. This chart shows the overall market risk appetite, reflecting investors' willingness to invest in companies vying for share in the complex pharmaceutical market.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Akebia Therapeutics
Akebia is a biopharmaceutical company focused on treating anemia associated with chronic kidney disease (CKD). Their key drug (Vadadustat) is an oral (tablet-based) alternative to EPO injections. This chart is a barometer of their turnaround. It likely reflects their ability to commercialize the drug (after approval) and their struggle for market share among dialysis patients.
AKIMA Market Segment Index - Pharma kidney
Akebia (AKBA) is a kidney-focused biotech; after a US failure, the company received approval for its oral (tablet) drug (Vafseo) for the treatment of anemia in dialysis patients. This summary metric evaluates R&D. The graph shows the segment average. This benchmark: how does this niche (anemia) model (AKBA) differentiate it from the average pharma company?
The AKIM Index for the overall market
Akebia Therapeutics is a biopharmaceutical company specializing in the treatment of kidney diseases. Its key product is Vafseo (anemia). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this company, which is transitioning to commercialization, stacks up against the broader economic trends impacting the healthcare sector.
